Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
Authors
Farahany, NA; Benatar, M; Wuu, J; Andersen, PM; Bucelli, RC; Andrews, JA; Otto, MCitation
Farahany, N. A., Benatar, M., Wuu, J., Andersen, P. M., Bucelli, R. C., Andrews, J. A., & Otto, M. (2022). Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. Neurotherapeutics, 19(4), 1248–1258.